Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)HKSE:02161 -1.34%86 3-Year ROIIC % is 43.71 as of Mar. 2026, which is 712% above its 10-year median of 5.38. GuruFocus rates HKSE:02161 with a GF Score™ of 86/100 and a GF Value™ of HK$2.09 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Drug Manufacturers companies, JBM (Healthcare) ranks better than 81.99% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
JBM (Healthcare)'s 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 43.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for JBM (Healthcare)'s 3-Year ROIIC % or its related term are showing as below:
HKSE:02161's 3-Year ROIIC % is ranked better than 81.99% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.565
vs HKSE:02161: 43.71
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
JBM (Healthcare) 3-Year ROIIC % Related Terms
JBM (Healthcare) 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JBM (Healthcare) 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where JBM (Healthcare)'s 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
JBM (Healthcare) (HKSE:02161) has a 3-Year ROIIC % of 43.71 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on JBM (Healthcare) and its competitors. This is 712% above median its historical median of 5.38. According to the industry distribution chart, JBM (Healthcare) ranks #170 out of 944 companies in the Drug Manufacturers industry, placing it in the top 18%.
Is JBM (Healthcare)'s 3-Year ROIIC % too high?
JBM (Healthcare)'s current 3-Year ROIIC % of 43.71 is 712% above median its 10-year median of 5.38. The Drug Manufacturers industry median 3-Year ROIIC % is 3.57. JBM (Healthcare)'s value of 43.71 is 1126.1% above this industry median. Based on the distribution chart, JBM (Healthcare) ranks #170 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JBM (Healthcare) ranks #170 out of 944 companies for 3-Year ROIIC %. This places JBM (Healthcare) in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.57. JBM (Healthcare)'s value of 43.71 is 1126.1% above this benchmark. While the company's 10-year median is 5.38 vs. the industry median of 3.57, JBM (Healthcare) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.57, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JBM (Healthcare)'s current 3-Year ROIIC % of 43.71 is 1126.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on JBM (Healthcare) and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JBM (Healthcare)'s current 3-Year ROIIC % is 43.71, which is 712% above median its own 10-year median of 5.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$2.09, compared to a current price of HK$1.84 — trading 12% below its estimated fair value. The current 3-Year ROIIC % is 43.71, which is 712% above median its 10-year median of 5.38 and 1126.1% above the Drug Manufacturers industry median of 3.57. JBM (Healthcare)'s overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current 3-Year ROIIC % is 43.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.84 is trading 12% below its estimated GF Value™ of HK$2.09.
GuruFocus considers JBM (Healthcare) to be Modestly Undervalued.
Key valuation signals for HKSE:02161:
3-Year ROIIC %: 43.71 (712% above median its 10-year median of 5.38)
GF Value™: HK$2.09 vs. price of HK$1.84 (12% below fair value)
Industry Position: 1126.1% above the Drug Manufacturers median (#170 of 944)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
